Sanofi US News
WEB6 days ago · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB3 days ago · Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB5 days ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB5 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up...
Dupixent Gets FDA Approval for COPD - WebMD
WEB21 hours ago · Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval...
Dupixent® (dupilumab) Approved in China as the First-ever …
WEB5 days ago · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic
WEB5 days ago · (RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved Dupixent as an add-on maintenance treatment of...
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBNov 27, 2023 · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in …
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB5 days ago · (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the...
Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEB3 days ago · The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary...